C.H. Robinson to Acquire RXO in $5.8 Billion Cash-and-Stock Deal

C.H. Robinson Worldwide and RXO Inc. said on Oct. 5, 2026 that they have entered a definitive merger agreement under which C.H. Robinson will acquire RXO in a stock-and-cash transaction with an implied value of $5.8 billion, according to a joint announcement carried by FT Business Wire and reported by Seeking Alpha Market News. The companies said the combination would create a company with an enterprise value of more than $25 billion, bringing together both firms' brokerage, transportation, forwarding and expedited operations in North America.

Deal Terms and Premium

Under the agreement, RXO stockholders are set to receive $17.25 per share in cash plus 0.0856 shares of C.H. Robinson common stock for each RXO share held, an implied total consideration of $30.25 per share, according to the companies' statement. That figure is based on C.H. Robinson's 16-day volume-weighted average price of $151.88 as of Oct. 2, 2026, the companies said.

RXO holders will also have the option to elect all-cash consideration of $30.25 per share or all-stock consideration of 0.1992 C.H. Robinson shares, subject to proration mechanics designed to keep the aggregate mix at roughly 57% cash and 43% stock, per the announcement. The companies said the deal represents a premium of 29% to RXO's closing price on Oct. 2, 2026, and 27% to RXO's 90-day volume-weighted average price. By our calculation, the gap between those two premium figures is 2 percentage points (29 minus 27), a relative difference of about 7.4% between the two benchmarks, illustrating that the headline premium looks somewhat richer against a single-day close than against RXO's trailing three-month trading average.

Upon closing, RXO stockholders are expected to own 11% of the combined company, the companies said. RXO will be folded primarily into C.H. Robinson's North American Surface Transportation (NAST) division, according to the announcement.

Synergies, Financing and the Buyback Pause

C.H. Robinson said it expects approximately $300 million of net run-rate cost synergies within two years of closing, drawn from cost-to-serve opportunities, operating efficiencies, shared-services savings and third-party spend optimization as the company applies its Lean AI operating model to RXO's business. The company said it expects the deal to be accretive to adjusted EPS within nine months of close and mid-teens accretive to adjusted EPS in 2028, a non-GAAP measure that excludes restructuring costs, loss from divestiture and acquisition-related intangible amortization, per the announcement.

The cash portion of the deal will be funded with new debt, backed by a fully underwritten bridge facility commitment from Morgan Stanley Senior Funding, Inc., the companies said. C.H. Robinson said it is targeting de-leveraging to a net debt-to-adjusted EBITDA range of 1.75x to 2.25x by the end of 2028, expects to maintain its investment-grade credit ratings, and intends to pause share repurchases until that target leverage is reached after closing, according to the statement. No change to the dividend was disclosed in the available materials.

Timeline, Approvals and Advisors

Both boards unanimously approved the merger agreement, and the companies said they expect the transaction to close in the first half of 2027, subject to customary conditions including regulatory approval and a vote of RXO stockholders. C.H. Robinson intends to file a Form S-4 registration statement with the SEC that will include a preliminary proxy statement for RXO shareholders that also serves as a preliminary prospectus for C.H. Robinson, the companies said. They flagged completion risk in the filing language, noting that required stockholder or regulatory approvals may not be obtained, that litigation or regulatory action tied to the deal could arise, and that anticipated synergies may not be realized. No specific antitrust review timeline, regulatory body, or market-share figures for the combined business were disclosed in the available materials.

Morgan Stanley & Co. LLC is acting as financial advisor to C.H. Robinson, with Gibson, Dunn & Crutcher LLP as legal counsel, the companies said. Goldman Sachs & Co. LLC is advising RXO, with Paul, Weiss, Rifkind, Wharton & Garrison LLP as its legal counsel.

Shareholder Support and Executive Comments

MFN Partners LP, which holds approximately 17% of RXO shares, has agreed to vote in favor of the transaction and, subject to certain exceptions, not to transfer its shares, according to the announcement. Adam R. Karr, President and Portfolio Manager at Orbis Investments, said Orbis is RXO's largest shareholder and has owned the company since it became independent, adding that the deal "gives RXO shareholders substantial cash today and continued ownership in a combined platform with significant upside."

C.H. Robinson President and CEO Dave Bozeman described the deal as "a natural next step in our transformation, allowing us to create a more scaled, resilient North American third-party logistics provider." RXO Chairman and CEO Drew Wilkerson said joining C.H. Robinson "represents an exciting next chapter for our company, our employees and our customers."

Context

The RXO transaction follows a smaller C.H. Robinson acquisition earlier this year: the company closed a $75 million all-cash purchase of Illinois-based DeSpir Logistics on June 22, 2026, a company that reported $62 million in revenue in its last fiscal year, according to CDLLife. The RXO deal is substantially larger in scale and strategic scope, combining brokerage, transportation, forwarding and expedited capabilities the companies say will create a denser logistics network. C.H. Robinson describes itself as serving 75,000 customers and 450,000 contract carriers, managing 37 million shipments annually representing $23 billion in freight, per the company's own figures cited in the announcement.

Bottom Line

The announced terms give RXO holders a defined, if still conditional, path to $30.25 per share in blended cash and stock, a premium the companies peg between 27% and 29% depending on the reference price. The deal's completion depends on regulatory clearance and an RXO shareholder vote, with closing targeted for the first half of 2027; until then, the specifics of synergy capture, de-leveraging and any antitrust scrutiny of the combination remain forward-looking commitments from the companies rather than completed facts.